Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and HPLC-verified to >99% purity . Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a full sealed 10-vial research pack for a complete study supply, or add a single-vial sample alongside your pack to trial a new compound first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

What It's Researched For

In plain terms, Cartalax is studied as a "bioregulator" peptide aimed at connective tissue and cartilage. Here is what that looks like across the research.

Cartilage & connective tissue

Research explores how this tiny peptide influences the cells that build and maintain cartilage and connective tissue as they age.

Gene-expression research

Studied as a tissue-specific switch that can nudge which genes connective-tissue cells turn on or off - the core idea behind the Khavinson "bioregulator" peptides.

Tissue-ageing models

Used as a reference compound in cell-culture work on how connective tissue loses function with age.

Bioregulator family tool

Sits alongside Epitalon and Vesugen as a well-defined member of the short-peptide bioregulator family for comparative research.

Overview

In short: Cartalax (Ala-Glu-Asp, "AED") is a three-amino-acid peptide bioregulator from the Khavinson cytogen family, studied for tissue-specific gene modulation in cartilage and connective-tissue cell models.

Key research facts

Synthetic Ala-Glu-Asp (AED) tripeptide from the Khavinson short-peptide bioregulator lineage

Studied as a tissue-specific transcriptional modulator in connective-tissue and cartilage cell cultures

Investigated for effects on chondrocyte and fibroblast proliferation in ageing-tissue models

Examined for modulation of matrix-remodelling and pro-inflammatory signalling markers in vitro

Belongs to the same "cytogen" peptide family as Epitalon (AEDG) and Vesugen (KED)

These points summarise lab themes, not human outcomes.

Cartalax is one of the shortest peptides you will find in research use - just three amino acids (Ala-Glu-Asp). It comes from the Russian "bioregulator peptide" programme led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, the same group behind Epitalon (the pineal AEDG tetrapeptide) and Vesugen (the vascular KED tripeptide).

The programme's guiding idea is that the body uses very short peptides as tissue-specific regulators: small enough to enter the nucleus, they are proposed to bind particular sequences in genomic DNA and influence which genes a given tissue expresses. Each cytogen peptide is matched to a tissue - and Cartalax is the connective-tissue / cartilage member of that set. In cultured chondrocyte and fibroblast models it has been studied for its effect on cell proliferation and on the expression of matrix-remodelling and inflammatory-signalling markers tied to connective-tissue ageing.

Cartalax is supplied here as a research-grade lyophilised powder for in-vitro and preclinical work only. It is not an approved medicine in any jurisdiction, and nothing on this page is medical advice.

Mechanism of Action

Cartalax is studied as a tissue-specific transcriptional modulator: the Khavinson model proposes that short peptides enter the nucleus, bind defined promoter sequences, and shift gene expression toward a more youthful pattern in their target tissue - for Cartalax, connective tissue and cartilage.

Pathway Effect Why it matters Short-peptide nuclear entry Small enough to reach the nucleus and contact genomic DNA Mechanistic basis for the proposed direct gene-regulatory action Promoter-sequence binding Proposed binding to specific DNA motifs in target-gene promoters Tissue-specific transcriptional regulation rather than broad signalling Connective-tissue gene modulation Studied for effects on chondrocyte / fibroblast proliferation markers Relevance to cartilage and connective-tissue maintenance research Matrix & inflammation markers Examined for influence on matrix-remodelling and pro-inflammatory / pro-apoptotic markers in vitro Probes the connective-tissue ageing phenotype in cell culture

Deeper dive for scientific readers

Cartalax belongs to the "cytogen" class of short synthetic peptides characterised by the Khavinson group, whose foundational hypothesis is that 2–4 residue peptides act as endogenous gene regulators binding specific DNA sequences. Published work on this peptide family describes tissue-matched effects on gene expression and cell proliferation in vitro; the cartilage/connective-tissue assignment of Cartalax (AED) follows that same matched-tissue logic. Formal human pharmacokinetic and controlled clinical efficacy data for Cartalax specifically have not been published, so the mechanism is best framed as a research hypothesis supported by cell-culture and animal studies rather than established human pharmacology.

Common Questions People Are Asking

What is Cartalax used for in research?

Cartalax (Ala-Glu-Asp / AED) is studied as a tissue-specific short-peptide bioregulator focused on cartilage and connective tissue. Research has examined its influence on chondrocyte and fibroblast proliferation and on gene-expression markers tied to connective-tissue ageing, mostly in cell-culture and animal models.

What does "AED" mean and how is Cartalax related to Epitalon?

AED is the one-letter code for the sequence Alanine-Glutamate-Aspartate - the three amino acids that make up Cartalax. It belongs to the same Khavinson "cytogen" peptide family as Epitalon (AEDG, four residues) and Vesugen (KED). They share a common design idea - very short peptides acting as tissue-specific gene regulators - but each is matched to a different tissue, with Cartalax assigned to cartilage / connective tissue.

How is Cartalax proposed to work?

The Khavinson bioregulator model proposes that short peptides like Cartalax are small enough to enter the cell nucleus, bind specific promoter sequences in DNA, and modulate the transcription of genes in their target tissue. For Cartalax that target is connective tissue. This is a research hypothesis supported by in-vitro and animal data rather than established human pharmacology.

Is there human clinical data for Cartalax?

No controlled human pharmacokinetic or efficacy data for Cartalax specifically has been published. Most of the evidence comes from cell-culture and animal studies on the short-peptide bioregulator family. It remains a research compound, not a validated therapy, and is sold here strictly for laboratory use.

How should Cartalax be stored?

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water or sterile saline, refrigerate at 1–6 °C and protect from light. As a small, simple tripeptide it tolerates standard peptide-handling conditions well within the normal usage window.

Where can I buy Cartalax?

Right here - Cartalax is supplied directly by New-U Research Compounds on this page. Every batch is independently third-party tested to >99% HPLC purity with a batch-linked Certificate of Analysis, supplied as lyophilised research-grade material, and shipped direct from source worldwide in discreet, tracked packaging.

How much does Cartalax cost?

Cartalax pricing is shown live on this page, per pack size - 10-vial research packs as standard, with single-vial sample options on selected compounds. Larger vial strengths lower the per-mg cost, every order includes the batch Certificate of Analysis, and shipping is free on orders over $300.

Is Cartalax third-party tested?

Yes. Every Cartalax batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC. Every order ships with its COA, and current batch certificates are published on our COA page.

How do I buy Cartalax?

Add the Cartalax pack size you need to your cart and check out: enter your shipping details, then choose your payment method - cryptocurrency or card - on the next step. Every order ships with its batch Certificate of Analysis (COA).

What payment methods can I use to buy Cartalax?

At checkout you can pay by cryptocurrency (BTC, ETH, SOL, LTC, USDC, USDT and more) or by card, each handled by a dedicated secure payment provider. You choose your method after confirming your order.

How fast is shipping, and do you ship worldwide?

Yes - we ship worldwide in discreet, unmarked, temperature-stable, tracked packaging. Delivery typically takes 6–14 business days, and shipping is free on orders over $300.

Is it legal to buy Cartalax?

In the United States, Cartalax is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Stability Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. Notes Formal human pharmacokinetic parameters (t½, Vd, bioavailability) have not been published for Cartalax. As a tripeptide (MW 333.30 Da) it is subject to rapid peptidase hydrolysis releasing its constituent amino acids. Subcutaneous and intraperitoneal routes are standard in the published short-peptide literature; oral bioavailability is not characterised. These figures describe the research literature and are not a dosing recommendation.

Evidence Tier

Overall: Tier 3: Anecdotal / self-report

Cartalax has minimal published evidence: no controlled human pharmacokinetic or efficacy data exist for the compound specifically, and the supporting data are generic cell-culture and animal studies of the Khavinson "cytogen" short-peptide bioregulator family rather than Cartalax itself. Its tissue-specific gene-regulation mechanism is a research hypothesis, not established pharmacology. It has no Western regulatory approval and is supplied as unapproved laboratory material.

Certificates, databases & peer-reviewed sources

Last reviewed: 26 June 2026 · New-U Research Compounds

PubMed: peer-reviewed literature on Cartalax

ClinicalTrials.gov: registered studies on Cartalax

Cartalax: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

Three-amino-acid tripeptide (Ala-Glu-Asp / AED)

Member of the Khavinson "cytogen" short-peptide bioregulator family

Connective-tissue / cartilage-matched member of the cytogen set

Proposed tissue-specific transcriptional modulator

Same research lineage as Epitalon (AEDG) and Vesugen (KED)

Typical research cycle: short pulsed SC course (e.g. 10–20 days)

No published human pharmacokinetic data - research compound only

Research-grade purity: 99.31% HPLC (Janoshik #196370)

Specifications

Molecular Formula C 12 H 19 N 3 O 8 Molecular Weight 333.30 Da Sequence Ala-Glu-Asp (AED) Purity 99.31% (HPLC) Form Lyophilised powder Family Khavinson cytogen short-peptide bioregulator Route Subcutaneous or intraperitoneal injection Solubility Bacteriostatic water or sterile saline Storage Lyophilised: −20 °C freezer. Reconstituted: 1-6 °C, away from light.

About Cartalax (AED): Connective-Tissue Peptide Bioregulator Research Guide

Cartalax sits inside one of the more distinctive research lineages in peptide science - the Russian "bioregulator peptide" programme run by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Over several decades that group characterised a series of very short peptides (two to four amino acids) which they proposed act as endogenous, tissue-specific gene regulators. Each peptide in the set is matched to a tissue; Cartalax, the Ala-Glu-Asp (AED) tripeptide, is the connective-tissue and cartilage member of the family.

The mechanism that defines the whole family is direct gene regulation by short peptides. The hypothesis is that these peptides are small enough to enter the nucleus, bind specific promoter sequences in DNA, and shift transcription toward a more youthful expression pattern in their target tissue. For Cartalax that means research interest in chondrocyte and fibroblast behaviour - proliferation, matrix remodelling, and the inflammatory-signalling markers associated with connective-tissue ageing - studied largely in cell-culture and animal models rather than controlled human trials.

New-U Research Compounds supplies Cartalax as a research-grade lyophilised powder at 99.31% HPLC purity, verified by an independent third-party lab (Janoshik, task #196370, June 2026). All material is strictly for in-vitro and preclinical research use. Cartalax is not approved for human therapeutic use in any major jurisdiction, and nothing on this page constitutes medical advice or a dosing recommendation.

Peptide - Wikipedia

Epithalon (Khavinson bioregulator context) - Wikipedia

Cartilage - Wikipedia

Chondrocyte - Wikipedia

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic / Longevity

Cartalax vs related Metabolic / Longevity compounds

Compound Price Purity spec COA Cartalax from $150 99.31% HPLC On request MOTS-C from $139 >99% HPLC 1 published batch 5-Amino-1MQ from $89 >99% HPLC On request

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Cartalax

Cartalax research guide

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.